Speaker Series: Treating to Target in Gout – a new option

This publication is a summary of presentations given by Clinical Associate Professor Neil McGill (Australia) and Associate Professor Fernando Perez-Ruiz (Spain) at a breakfast symposium on 26th May 2015 at the Australian Rheumatology Association Scientific Meeting held at the Adelaide Convention Centre.

Associate Professor McGill addressed the new practical application of gout treatments in Australia within the current regulatory and financial restraints. Associate Professor Perez-Ruiz discussed the biochemistry behind urate-lowering therapy,
hyperuricaemia and gout, gout’s impact on humans and the importance of long-term urate-lowering
therapy. Associate Professor Perez-Ruiz also reviewed the data from phase 3 and open label extension
trials of febuxostat.

Please login below to download this issue (PDF)

Subscribe